

ORAL PRESENTATION

Open Access

PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer

Jay M Lee*, Edward B Garon, Mi-Heon Lee, Gerald Wang, Dörthe Schauen, Felicita Baratelli, Fereidoun Abtin, Robert Suh, William D Wallace, Gang Zeng, Sherven Sharma, Steven M Dubinett

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Background

Anti-tumor immune response in lung cancer patients may be evoked by intra-tumoral (IT) administration of autologous dendritic cells (DC), transduced with a replication-deficient adenoviral (Ad) vector to express the secondary lymphoid chemokine (SLC/CCL21) gene. Here, we evaluated tumor specific immune response after CCL21 gene-modified DC (Ad-CCL21-DC) administration in the context of tumor PD-L1 expression.

Methods

Phase I, non-randomized, dose escalating, multi-cohort trial was conducted to enroll patients with Stage IIIB/IV NSCLC. Sixteen patients received 2 vaccinations at a dose of Ad-CCL21-DC (A, B, C, or D; 1×10^6 , 5×10^6 , 1×10^7 , or 3×10^7 cells/injection) by IT injection (days 0 and 7). Peripheral blood was collected for antigen-specific ELISPOT assays, and CT guided needle biopsies of the primary lung cancer were obtained for PD-L1 expression by real time PCR and evaluation of cellular infiltrates by immunohistochemistry.

Results

Peripheral blood of 16 subjects was evaluated by ELISPOT assays. Positive response was defined as 2-fold increase in number of spots above background with an absolute number of >20 spots/ 2×10^5 cells (positive responder; PR). A mixed response was defined as a positive response with high IFN- γ background expression at day 0 compared to post-vaccine time points (mixed responder; MR). There were 19% (3/16) PR and 19% (3/16) MR for a total of 38% (6/16) total responders. The average PD-L1 gene copy

number was 1344 (non-responder; NR) compared to 394 (MR), and 684 (PR) on day 7. Tumor CD8 T cell infiltration was induced in 40% (6/15; all subjects), 33% (3/9; NR), and 50% (3/6; MR & PR).

Conclusion

Intra-tumoral administration of autologous dendritic cells expressing the SLC/CCL21 gene demonstrated that 1) anti-tumor specific immune responses are elicited and correlate with lower PD-L1 expression, and 2) CD8 T cell infiltration into the tumor is induced.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-O20

Cite this article as: Lee et al.: PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):O20.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



University of California, Los Angeles, CA, USA



© 2014 Lee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.